GSK Pharma Board to Consider FY26 Results, Dividend

GSK Pharma's board will meet on 13th May 2026 to approve audited standalone and consolidated financial results for the year ended 31st March 2026.
The board will also consider recommending a dividend, if any, for the company's equity shareholders during this meeting.
This disclosure is made pursuant to Regulation 29 and 33 of the SEBI LODR Regulations, 2015 for compliance purposes.